Plasma, urine, and skin drug concentrations were determined for dogs (n=12) given five daily oral doses of marbofloxacin (MAR) (2.75 mg/kg), enrofloxacin (ENR) (5.0 mg/kg) or difloxacin (DIF) (5.0 mg/kg). Concentrations of the active metabolite of ENR, ciprofloxacin (CIP), were also determined. The three-period, three-treatment crossover experimental design included a 21-day washout period between treatments. Area under the plasma drug concentration vs. time curve (AUC0-last, microg/mLxh of MAR was greater than for ENR, CIP, ENR/CIP combined, and DIF. Maximum concentration (Cmax) of MAR was greater than ENR, CIP, and DIF. Time of maximum plasma concentration (Tmax) was similar for MAR and DIF; Tmax occurred earlier for ENR and later for CIP. Plasma half-life (t1/2) of MAR was longer than for ENR, CIP, and DIF. Urine concentrations of DIF were less than MAR or ENR/CIP combined, but urine concentrations of MAR and ENR/CIP combined did not differ. DIF skin concentrations were less than the concentrations of MAR or ENR/CIP combined 2 h after dosing, but skin concentrations of MAR and ENR/CIP combined did not differ.
The effects of zilpaterol hydrochloride (ZH) on blood metabolites and fatty acid profiles of plasma and adipose tissue were evaluated in crossbred finishing steers (n = 18, BW 639 ± 12.69 kg) that were stratified by BW and randomly assigned, within strata (block), to receive 0 (control) or 8.33 mg/kg diet DM ZH. Cattle were fed once daily ad libitum in individual feeding pens (9 pens/treatment). Zilpaterol hydrochloride was fed for 23 d and withdrawn 3 d before harvest. Blood samples and measures of BW were taken on d 0, 7, 14, and 21. Concentrations of β-hydroxybutyrate (BHB), glucose, and lactate were determined from whole blood. Nonesterified fatty acids, urea nitrogen (PUN), glucose, lactate, and long-chain fatty acid (LCFA) concentrations were analyzed from plasma. Postharvest, adipose tissue samples (approximately 20 g) from subcutaneous fat covering the lumbar vertebrae were collected after 48 h of refrigeration and analyzed for LCFA profiles. Feeding ZH decreased DMI by 8% (P = 0.03) but did not affect BW gain or efficiency (P = 0.83 and P = 0.56, respectively). Addition of ZH resulted in greater HCW, dressing percentage, and LM area ( P = 0.02, P = 0.08, and P = 0.07, respectively) but did not influence other carcass traits (P > 0.10). A ZH × d interaction was observed for PUN and whole-blood glucose concentrations (P = 0.06), in which concentrations decreased in cattle receiving ZH. Nonesterified fatty acids, BHB, plasma glucose, whole-blood, and plasma lactate concentrations were unaffected by ZH (P > 0.10). Zilpaterol hydrochloride increased plasma concentrations of elaidic (P = 0.03), vaccenic (P = 0.006), and docosapentaenoic acids ( P= 0.08), but LCFA concentrations of adipose tissue were unaffected ( P> 0.10), suggesting no preferential oxidation of specific fatty acids. In conclusion, ZH supplementation decreased PUN concentration possibly due to decreased muscle catabolism, but components of blood related to lipid oxidation were unaffected.
The thin agar layer (TAL) method of Kang and Fung was used to enumerate acid-injured foodborne pathogens. This method involves overlaying 14 ml of nonselective medium (tryptic soy agar [TSA]) onto a prepoured and solidified pathogen-specific, selective medium in a petri dish. After surface plating, injured cells resuscitated and grew on TSA during the first few hours of incubation; then, the selective agents from the selective medium diffused to the top layer, interacted with the recovered microorganisms, and started to produce typical reactions. Foodborne pathogens were exposed to 2% acetic acid for 1, 2, or 4 min, and the recovery rate with the TAL method was compared with the rate of TSA and pathogen-specific, selective media. No significant difference occurred between TSA and TAL (P > 0.05) for enumeration of acid-injured Escherichia coli O157:H7, Salmonella Typhimurium, Staphylococcus aureus, and Yersinia enterocolitica, and both recovered significantly higher numbers than the selective medium for each respective pathogen (P < 0.05). For recovery of acid-injured Listeria monocytogenes, no difference (P > 0.05) occurred among TSA, TAL, and selective media. However, fewer cells were recovered in the selective media. The TAL method is a one-step, convenient procedure for recovery of acid-injured cells.
of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs. J. vet. Pharmacol. Therap. 23,[293][294][295][296][297][298][299][300][301][302] Plasma, urine, and skin drug concentrations were determined for dogs (n= 12) given five daily oral doses of marbofloxacin (MAR) (2.75 mg/kg), enrofloxacin (ENR) (5.0 mg/kg) or difloxacin (DIF) (5.0 mg/kg). Concentrations of the active metabolite of ENR, ciprofloxacin (CIP), were also determined. The three-period, three-treatment crossover experimental design included a 21-day washout period between treatments. Area under the plasma drug concentration vs. time curve (AUC 0-last , mg/mL × h of MAR was greater than for ENR, CIP, ENR/CIP combined, and DIF. Maximum concentration (C max ) of MAR was greater than ENR, CIP, and DIF. Time of maximum plasma concentration (T max ) was similar for MAR and DIF; T max occurred earlier for ENR and later for CIP. Plasma half-life (t 1/2 ) of MAR was longer than for ENR, CIP, and DIF. Urine concentrations of DIF were less than MAR or ENR/CIP combined, but urine concentrations of MAR and ENR/CIP combined did not differ. DIF skin concentrations were less than the concentrations of MAR or ENR/CIP combined 2 h after dosing, but skin concentrations of MAR and ENR/CIP combined did not differ.(Paper
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.